Tannic acid-based supramolecular nanoparticles offer promise for the oral delivery of anti-tumour necrosis factor alpha (TNF-α) antibodies in the treatment of experimental IBD; this approach is characterized by less systemic side effects due to enhanced accumulation in inflamed colon tissue [74]. Here, TNF is linked to inflammatory bowel disease.